Loading...

TARA PROTARA THERAPEUTICS INC US FDA Inspections 8-K Filing

PRTR

TR

PROTARA THERAPEUTICS INC

(TARA)

2026 8-K

Annual Meeting Results

Financial Results Announcement

Clinical Trial Update

Financial Results Report

Study Results Update

Equity Offering Details

Stock Offering Details

Investor Update

Investor Presentation Released

Financial Results Report

Financial Statements

Financial Results

Clinical Trial Update

Financial Results

Financial Results Announcement

Annual Meeting of Stockholders

Financial Results Announcement

Private Placement

Resignation of Chief Medica...

Financial Results Announcement

Financial Results Announcement

Financial Results Announcement

Annual Meeting of Stockholders

Financial Results Announcement

FDA Clearance for Phase 2 T...

Positive Preliminary Data A...

Disclosure of Cash Holdings...

Financial Results Announcement

Appointment of CFO

Corporate Presentation

External Links:

On March 30, 2026, Protara Therapeutics reported a six-month complete response rate of 68.0% for the 25 BCG-Unresponsive patients in its Phase 2 trial of TARA-002, consistent with a previous report and well above the 41.9% benchmark.

AI Assistant

PROTARA THERAPEUTICS INC

2026

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.